{
    "id": 7872,
    "fullName": "CXCR4 S338*",
    "impact": "nonsense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CXCR4 S338* results in a premature truncation of the Cxcr4 protein at amino acid 388 of 352 (UniProt.org). S338* results in dysregulation of Cxcr4 internalization, leading to continued activation of Akt and Erk in cell culture (PMID: 24912431).",
            "references": [
                {
                    "id": 3107,
                    "pubMedId": 24912431,
                    "title": "The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24912431"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7852,
        "geneSymbol": "CXCR4",
        "terms": [
            "CXCR4",
            "CD184",
            "D2S201E",
            "FB22",
            "HM89",
            "HSY3RR",
            "LAP-3",
            "LAP3",
            "LCR1",
            "LESTR",
            "NPY3R",
            "NPYR",
            "NPYRL",
            "NPYY3R",
            "WHIM",
            "WHIMS"
        ]
    },
    "variant": "S338*",
    "createDate": "06/19/2015",
    "updateDate": "06/19/2015",
    "referenceTranscriptCoordinates": {
        "id": 170940,
        "transcript": "NM_003467",
        "gDna": "chr2:g.136114915G>T",
        "cDna": "c.1013C>A",
        "protein": "p.S338*",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 7385,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, expression of CXCR4 S338* in Waldenstrom macroglobulinemia cell lines conferred resistance to Imbruvica (ibrutinib) induced apoptosis in the presence of the Cxcr4 ligand Cxcl12 (Sdf-1a) in culture (PMID: 24912431).",
            "molecularProfile": {
                "id": 7764,
                "profileName": "CXCR4 S338*"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3107,
                    "pubMedId": 24912431,
                    "title": "The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24912431"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7386,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mozobil (plerixafor) to treament with Imbruvica (ibrutinib) overcame resistance to Imbruvica (ibrutinib), resulting in apoptosis in Waldenstrom macroglobulinemia cell lines expressing CXCR4 S338* cultured in the presence of the Cxcr4 ligand, Cxcl12 (Sdf-1a) (PMID: 24912431).",
            "molecularProfile": {
                "id": 7764,
                "profileName": "CXCR4 S338*"
            },
            "therapy": {
                "id": 2969,
                "therapyName": "Ibrutinib + Plerixafor",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3107,
                    "pubMedId": 24912431,
                    "title": "The WHIM-like CXCR4(S338X) somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24912431"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2623,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S338* demonstrated resistance to Imbruvica (Ibrutinib) in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9806,
                "profileName": "CXCR4 S338* MYD88 L265P"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2626,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, co-treatment with Mozobil (plerixafor) overcame resistance to Imbruvica (Ibrutinib) in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S338* in the presence of CXCL12 in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9806,
                "profileName": "CXCR4 S338* MYD88 L265P"
            },
            "therapy": {
                "id": 2969,
                "therapyName": "Ibrutinib + Plerixafor",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2629,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with IMG-2005-5 induced apoptosis in Waldenstrom macroglobulinemia cells harboring MYD88 L265P and expressing CXCR4 S338* in culture (PMID: 25371371).",
            "molecularProfile": {
                "id": 9806,
                "profileName": "CXCR4 S338* MYD88 L265P"
            },
            "therapy": {
                "id": 2868,
                "therapyName": "IMG-2005-5",
                "synonyms": null
            },
            "indication": {
                "id": 50747,
                "name": "lymphoplasmacytic lymphoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 3354,
                    "pubMedId": 25371371,
                    "title": "CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenstr\u00f6m macroglobulinaemia cells.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25371371"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 7764,
            "profileName": "CXCR4 S338*",
            "profileTreatmentApproaches": [
                {
                    "id": 5848,
                    "name": "CXCR4 Inhibitor",
                    "profileName": "CXCR4 S338*"
                }
            ]
        },
        {
            "id": 9806,
            "profileName": "CXCR4 S338* MYD88 L265P",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 170940,
            "transcript": "NM_003467",
            "gDna": "chr2:g.136114915G>T",
            "cDna": "c.1013C>A",
            "protein": "p.S338*",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}